Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-10 of 10

Sort by

Sort Order Select

Journal Articles

HSP90 Inhibitor–SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors

David A. Proia, Donald L. Smith, Junyi Zhang, John-Paul Jimenez, Jim Sang, Luisa Shin Ogawa, Manuel Sequeira, Jaime Acquaviva, Suqin He, Chaohua Zhang, Vladimir Khazak, Igor Astsaturov, Takayo Inoue, Noriaki Tatsuta, Sami Osman, Richard C. Bates, Dinesh Chimmanamada, Weiwen Ying

Mol Cancer Ther (2015) 14 (11): 2422–2432.

https://doi.org/10.1158/1535-7163.MCT-15-0455

Published: 03 November 2015

View article titled, HSP90 Inhibitor–SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors

Includes: Supplementary data

Journal Articles

Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib

Jaime Acquaviva, Donald L. Smith, John-Paul Jimenez, Chaohua Zhang, Manuel Sequeira, Suqin He, Jim Sang, Richard C. Bates, David A. Proia

Mol Cancer Ther (2014) 13 (2): 353–363.

https://doi.org/10.1158/1535-7163.MCT-13-0481

Published: 09 February 2014

View article titled, Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib

Includes: Supplementary data

Journal Articles

Abstract C130: The Hsp90 inhibitor ganetespib promotes the degradation of FGFR3 in bladder cancer models and induces regression in tumors harboring oncogenic FGFR3 fusions.

Jaime L. Acquaviva, Chaohua Zhang, Suqin He, John-Paul Jimenez, Masa Nagai, Jim Sang, Manuel Sequeira, Donald L. Smith, Margaret A. Knowles, David A. Proia

Mol Cancer Ther (2013) 12 (11_Supplement): C130.

https://doi.org/10.1158/1535-7163.TARG-13-C130

Published: 01 November 2013

View article titled, Abstract C130: The Hsp90 inhibitor ganetespib promotes the degradation of FGFR3 in bladder cancer models and induces regression in tumors harboring oncogenic FGFR3 fusions.

Journal Articles

Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib

Jaime Acquaviva, Donald L. Smith, Jim Sang, Julie C. Friedland, Suqin He, Manuel Sequeira, Chaohua Zhang, Yumiko Wada, David A. Proia

Mol Cancer Ther (2012) 11 (12): 2633–2643.

https://doi.org/10.1158/1535-7163.MCT-12-0615

Published: 09 December 2012

View article titled, Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib

Includes: Supplementary data

Journal Articles

Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

Weiwen Ying, Zhenjian Du, Lijun Sun, Kevin P. Foley, David A. Proia, Ronald K. Blackman, Dan Zhou, Takayo Inoue, Noriaki Tatsuta, Jim Sang, Shuxia Ye, Jamie Acquaviva, Luisa Shin Ogawa, Yumiko Wada, James Barsoum, Keizo Koya

Mol Cancer Ther (2012) 11 (2): 475–484.

https://doi.org/10.1158/1535-7163.MCT-11-0755

Published: 08 February 2012

View article titled, Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

Includes: Supplementary data

Journal Articles

Abstract C168: Cancer-selective mitochondrial copper transport by elesclomol results in potent single agent efficacy in multiple tumor types.

Jim Sang, Masazumi Nagai, Chaohua Zhang, Donald Smith, Manuel Sequeira, Luisa Shin Ogawa, Josephine Ye, Yuan Liu, Takayo Inoue, Dan Zhou, Keizo Koya, Yumiko Wada

Mol Cancer Ther (2011) 10 (11_Supplement): C168.

https://doi.org/10.1158/1535-7163.TARG-11-C168

Published: 12 November 2011

View article titled, Abstract C168: Cancer-selective mitochondrial copper transport by elesclomol results in potent single agent efficacy in multiple tumor types.

Journal Articles

Abstract B105: Ganetespib, a unique resorcinolic Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile in preclinical models.

Weiwen Ying, David A. Proia, Dan Zhou, Takayo Inoue, Noriaki Tatsuta, Jim Sang, Shuxia Ye, Jaime Acquaviva, Luisa Shin Ogawa, Yumiko Wada, Dinesh Chimmanamada, Shijie Zhang, Keizo Koya

Mol Cancer Ther (2011) 10 (11_Supplement): B105.

https://doi.org/10.1158/1535-7163.TARG-11-B105

Published: 12 November 2011

View article titled, Abstract B105: Ganetespib, a unique resorcinolic Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile in preclinical models.

Journal Articles

Abstract C91: Pharmacodynamic analysis of the Hsp90 inhibitor STA‐9090 in a lung cancer xenograft model supports an infrequent dosing schedule in the clinic

Kevin P. Foley, Takeshi Shimamura, Ron K. Blackman, Christa L. Borgman, Takayo Inoue, Tim Korbut, David Proia, Jim Sang, Luisa Shin Ogawa, Don Smith, Noriaki Tatsuta, Chaohua Zhang, Haili Zhang, Weiwen Ying, Geoffrey I. Shapiro, James Barsoum

Mol Cancer Ther (2009) 8 (12_Supplement): C91.

https://doi.org/10.1158/1535-7163.TARG-09-C91

Published: 10 December 2009

View article titled, Abstract C91: Pharmacodynamic analysis of the Hsp90 inhibitor STA‐9090 in a lung cancer xenograft model supports an infrequent dosing schedule in the clinic

Journal Articles

Abstract B199: In vitro and in vivo efficacy of the novel Hsp90 inhibitor STA‐9090 and its synergy with paclitaxel

Mol Cancer Ther (2009) 8 (12_Supplement): B199.

https://doi.org/10.1158/1535-7163.TARG-09-B199

Published: 10 December 2009

View article titled, Abstract B199: In vitro and in vivo efficacy of the novel Hsp90 inhibitor STA‐9090 and its synergy with paclitaxel

Journal Articles

The oxidative stress inducer STA-4783 enhances the in vivo efficacy of multiple anti-cancer therapies in mouse tumor models

Kevin Foley, John Bertin, Kwan Chan, Amy Hutchings, Takayo Inoue, Jessica Kirshner, Timothy Korbut, Long Li, Robert Mihalek, Patricia Rao, Jim Sang, Don Smith, Noriaki Tatsuta, Chaohua Zhang, Dan Zhou, James Barsoum

Mol Cancer Ther (2007) 6 (11_Supplement): A290.

Published: 01 November 2007

View article titled, The oxidative stress inducer STA-4783 enhances the in vivo efficacy of multiple anti-cancer therapies in mouse tumor models

NARROW

HSP90 Inhibitor–SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors

Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib

Abstract C130: The Hsp90 inhibitor ganetespib promotes the degradation of FGFR3 in bladder cancer models and induces regression in tumors harboring oncogenic FGFR3 fusions.

Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib

Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

Abstract C168: Cancer-selective mitochondrial copper transport by elesclomol results in potent single agent efficacy in multiple tumor types.

Abstract B105: Ganetespib, a unique resorcinolic Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile in preclinical models.

Abstract C91: Pharmacodynamic analysis of the Hsp90 inhibitor STA‐9090 in a lung cancer xenograft model supports an infrequent dosing schedule in the clinic

Abstract B199: In vitro and in vivo efficacy of the novel Hsp90 inhibitor STA‐9090 and its synergy with paclitaxel

The oxidative stress inducer STA-4783 enhances the in vivo efficacy of multiple anti-cancer therapies in mouse tumor models

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only